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Diabetes: The importance of the liver
Guy A. Rutter
Insulin resistance, the hallmark of non-insulin
dependent diabetes mellitus, is characterized by the
failure of tissues to take up and store glucose in
response to insulin. Two recent studies shed new light
on the importance of insulin signalling in the liver and
how this may become defective in diabetes. 
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The predominant form of diabetes mellitus, non-insulin
dependent diabetes mellitus (NIDDM) or type 2 diabetes,
afflicts approximately 4% of the population of the Western
world, and its treatment consumes more than 10% of the
total National Health Service budget in Britain. The
disease is characterised by the failure of sensitive tissues to
respond normally to insulin — ‘insulin resistance’. These
tissues therefore fail to take up and store glucose, leading
to chronically elevated blood glucose (‘hyperglycaemia’).
In mild cases, increased insulin production by β cells in the
pancreatic islets of Langerhans — leading to ‘hyperinsuli-
naemia’ — can compensate for the decreased responsive-
ness to the hormone, but diabetes results when the islets
fail [1]. The causes of the disease remain poorly under-
stood, but its predominance amongst overweight individu-
als — 80% of type 2 diabetics are obese — suggests that
dysregulated lipid metabolism may be an important factor. 
The three major tissues largely responsible for clearing
glucose from the blood in healthy individuals — liver,
muscle and adipose tissue — all become insulin resistant
in NIDDM, but the relative importance of each has been
unclear. Two new studies [2,3] shed light on this question.
Michael et al. [2] have shown that targeted inactivation of
the insulin receptor gene specifically in the liver leads to
diabetes-like symptoms in mice. This is an important
result, as it demonstrates that insulin has a direct role in
regulating liver metabolism. Using two further animal
models, Shimomura et al. [3] found that the development
of insulin resistance in the liver involves selective inacti-
vation of the capacity of insulin to block hepatic glucose
production. On the other hand, the ability of the hormone
to stimulate fatty acid synthesis is retained. So, as well as
illuminating the importance of the liver as a target for
insulin action, these studies also provide new information
on the means by which the insulin receptor normally
signals into cells.
Loss of the liver insulin receptor causes hyperglycaemia
Michael et al. [2] used a targeted approach to knockout the
gene encoding that insulin receptor — a receptor tyrosine
kinase — specifically in the liver. As previously described
[4], this technique involves breeding mice in which the
wild-type insulin receptor gene has been replaced by one
flanked with recombinase-sensitive lox sites, with animals
expressing ‘Cre’ recombinase in a specific tissue, in this
case hepatocytes. This results in a liver-specific insulin
receptor gene knockout (‘LIRKO’) and severe insulin
resistance in young (two month-old) animals. The result-
ing appearance of overt glucose intolerance is in contrast
with the lack of effect of inactivating the insulin receptor
gene in muscle (‘MIRKO’) [5]. The latter result was unex-
pected, given that skeletal muscle is responsible for >70%
of glucose disposal following a carbohydrate meal [6], with
the liver accounting for most of the rest [7]. 
Importantly, the new results clearly demonstrate that
normal insulin signalling in the liver is important for
dealing with a glucose load. This resolves a long-standing
debate, as several groups (for example, [8]) have previ-
ously proposed that elevated glucose production by the
liver in starvation and diabetes may result only indirectly
from the absence of insulin. The fact that injection of
insulin failed to suppress glucose production by the liver
in the LIRKO animals, whilst presumably suppressing
lipolysis and the release of gluconeogenic precursors from
muscle, indicates that the direct effects of insulin on this
organ must be important in wild-type animals. 
The LIRKO animals also show extraordinarily elevated
(10–20-fold) levels of circulating insulin, as a result of the
expansion of the islet β-cell mass (to approximately five
times the normal level), hypersecretion of insulin and
decreased hepatic insulin disposal [2]. This last result was
expected, given that an active insulin receptor is necessary
to permit hepatocytes to internalise and degrade the
hormone. The mechanisms responsible for the spectacular
islet hyperplasia, seen also in other rodent models of dia-
betes [9], are unknown, but high blood glucose or insulin
levels, or some liver-derived developmental factor, may be
important. Interestingly, LIRKO animals do not suffer
from a failure of insulin secretion even after a year of
elevated insulin production — in humans, over-produc-
tion of insulin is believed to cause ‘β-cell exhaustion’ and
frank diabetes [10] (see below). It is uncertain, however,
how closely the mouse LIRKO model mirrors the human
condition where β-cell hyperplasia may be less pro-
nounced and thus the strain on the pre-existing β-cell
population correspondingly greater.
Selective changes in hepatic insulin receptor signalling 
Whilst the LIRKO mice are a powerful new tool for
investigating the importance of insulin signalling in the
liver [2], defects in the insulin receptor itself are not
believed to play a significant role in most forms of
NIDDM [11,12]. Michael et al. [2] therefore used two
models of insulin resistance, and examined hepatic gene
expression to explore the lesion in hepatic insulin
signalling. The first model is the well-known ob/ob mouse,
which lack the satiety factor, leptin, encoded by the obese
(ob) gene [13]. These animals over-eat, hypersecrete
insulin and develop fatty livers. The second model was
generated fortuitously when adipose tissue formation was
suppressed — a condition called lypodystrophy — by
expressing a dominant-negative form of the transcription
factor known as either adipose differentiation/determining
factor-1 (ADD1) or sterol response element binding
protein-1 (SREBP1) [14]. In the absence of extrahepatic
fat depots these mice, like the ob/ob animals, develop fatty
livers and become severely insulin resistant.
In both models of insulin resistance, the inductive action of
insulin on hepatic SREBP1 expression [15] is essentially
unaffected. SREBP1 is therefore able to transactivate
lipogenic genes, including those encoding glucokinase,
acetyl CoA carboxylase and fatty acid synthase. By this
means, hepatic lipid synthesis is expected to be enhanced.
By contrast, the genes encoding gluconeogenic enzymes
that are normally suppressed by insulin [16], such as
phophoenol pyruvate carboxykinase and glucose 6-phos-
phatase, are still expressed at high levels in the model mice.
Why should insulin be ineffective in regulating the
gluconeogenic genes, whilst still able to induce the lipogenic
genes? A likely explanation is that the levels of a key mol-
ecule in signalling from the insulin receptor — insulin
receptor substrate-2 (IRS2) — were dramatically reduced
in both models [3]. IRS2 and the other IRS isoforms [12]
are normally phosphorylated by the insulin receptor tyro-
sine kinase when insulin is bound, leading to the recruit-
ment of signalling molecules, notably phosphatidylinositol
3′-kinase. This in turn initiates protein kinase cascades —
for example, involving protein kinase B — leading ulti-
mately to the transcriptional and metabolic effects of the
hormone [12]. Consistent with these findings, IRS2 has
been shown to be important in hepatic insulin receptor
signalling [17], whilst less important in muscle [18]. By
contrast, the new data [3] show that the signalling pathway
leading from the insulin receptor to SREBP1 is largely
independent of IRS2.
Shimomura et al. [3] report evidence that the suppression
of the IRS2 gene is likely to be the result hyperinsuli-
naemia. When they cultured isolated hepatocytes with ele-
vated insulin concentrations, they found that IRS2 mRNA
levels decreased, whilst destruction of β cells in vivo with
streptozotocin caused an increase in the expression of IRS2
in the liver. 
Future directions
These results leave a number of intriguing questions unan-
swered. Firstly, do persistently elevated insulin levels cause
resistance in extrahepatic tissues, and can any such changes
be explained by a drop in IRS2 expression? Examination of
the level of expression of IRS2 in both the LIRKO and
MIRKO mice [5] may shed light on this question; IRS2
levels are expected to be elevated in insulin receptor-defi-
cient tissues but lower in other tissues [3]. Whether any
change in IRS2 expression in muscle would further con-
tribute to insulin resistance is, however, uncertain, given
the greater importance of IRS1 in this tissue [18]. 
Another question concerns the role of lipid accumulation
in decreasing IRS2 levels in ob/ob and lipodystrophic mice
livers [3]. Lipotoxicity is implicated in β-cell dysfunction
[19], and could result in part from SREBP1 overexpression
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Figure 1
A schematic illustration of the role of
insulinaemia in the development of insulin
resistance in the liver. Decreases in leptin
(and elevated blood glucose) provoke
enhanced insulin release from pancreatic
islets, leading to a reduction in hepatic IRS2
levels, decreased activation of PKB, and a
failure to suppress gluconeogenesis. At the
same time, increases in SREBP1c activate
lipogenic genes, prompting increased
lipogenesis and the release of fatty acids. The
latter, combined with glucose, cause further
insulin release, setting up a ‘vicious circle’.
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[20] (C. Zhao and G.A.R., unpublished data). In the
pancreatic β cell, IRS2 appears to be particularly important
in permitting feedforward effects of insulin [4,21], as
attested by the insulin secretory defect in IRS2–/– mice
[22]. Suppression of IRS2 expression in the β cell following
sustained hyperinsulinaemia might thus contribute to
defective insulin production in the long term. Such an idea
would represent an important paradigm shift as, up to now,
β-cell failure has generally been attributed to hypergly-
caemia (‘glucose toxicity’) [23,24].
Conclusions
Phosphorylation of IRS1 on serine (instead of tyrosine)
residues has previously been implicated in insulin
resistance caused by tumour necrosis factor α (TNFα) [25].
Taken with the new studies, this suggests that the IRS
family may be frequent targets of agents which cause
insulin resistance. These data also raise the question of
whether IRS2 is an important new candidate gene/predictor
for diabetes, though the answer from genetic screens seems
likely to be ‘no’ [26].
In the models described by Shimomura et al. [3], glucose
and fatty acid production by the liver are simultaneously
enhanced (Figure 1). This is likely to set up a feedforward,
or vicious circle, leading to further insulin resistance, as cir-
culating non-esterified fatty acids are likely to decrease the
responsiveness to insulin of both liver and other tissues [27].
Furthermore, increased hepatic glucose production will
enhance insulin release, causing the suppression of hepatic
IRS2, and insulin-mediated inhibition of gluconeogenesis.
As pointed out by Shimomura et al. [3], these results
support the suggestion by McGarry [28] that diabetes
should be considered not purely as a disease of glucose
homeostasis but, at least equally, of defective lipid metab-
olism. A major issue will be to determine whether similar
mechanisms for the development of hepatic insulin resis-
tance, as delineated here in the rodent, pertain in humans. 
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